Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06418659RecruitingEarly Phase 1
CD-801 for advanced liver cancer
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06583993RecruitingEarly Phase 1
Gene Therapy for Advanced Bile Duct Cancer
This early-phase trial tests a new kind of gene therapy (called HNF4α srRNA) given through a vein for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that has stopped responding to standard chemotherapy. The goal is to see if it is safe and if it can help slow or stop the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06621173RecruitingEarly Phase 1
Gene therapy for advanced colorectal cancer (dMMR/MSI-H)
This trial tests a new gene therapy (HNF4α SrRNA) given through a vein for people with advanced colorectal cancer that has a specific genetic marker (dMMR or MSI-H). It's for those who have already tried standard treatments without success or couldn't take them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07191457Recruiting
Testing two head lice treatments for safety and effectiveness
This study compares a new lice lotion to a standard lice shampoo to see how well they work and if they are safe. If you or your child has head lice, participating could help find a better way to get rid of them.
Enid, OklahomaAges 6 months+ - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07187531RecruitingPhase 2
Testing a new drug to preserve insulin production in type 1 diabetes
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
San Francisco, CaliforniaAges 5–40 - NCT07184827RecruitingPhase 3
U101 capsules to prevent recurring UTIs in women
This trial tests an oral capsule called U101 to see if it can prevent recurrent urinary tract infections (UTIs) in women who have frequent UTIs. If you've had at least 2 UTIs in the last 6 months or 3 in the last year, you may be able to join.
Chiayi CityAges 20–75 - NCT07185841RecruitingPhase 1/Phase 2
Oral tablets for wet macular degeneration
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
BeijingAges 50–85 - NCT07184944RecruitingPhase 3
Study of Duvakitug for moderate to severe Crohn's disease
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
Colorado Springs, ColoradoAges 16–80 - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Fullerton, CaliforniaAges 18 years+ - NCT07190196RecruitingPhase 3
Study of Rilzabrutinib for IgG4-related disease
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
Fontana, CaliforniaAges 18 years+ - NCT07187401RecruitingPhase 1/Phase 2
Study of a new RNA drug for PNH anemia
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
Toronto, OntarioAges 18 years+ - NCT07185269RecruitingPhase 1/Phase 2
Testing 626 for lupus: a phase 1/2 study
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
Beijing, Beijing MunicipalityAges 18–70 - NCT07192939RecruitingPhase 2
Testing HRS-9813 for progressive pulmonary fibrosis
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
Beijing, Beijing MunicipalityAges 21 years+ - NCT07191899RecruitingPhase 1
KN060 for treating high blood pressure
This trial tests a new medication called KN060 for people with high blood pressure (essential hypertension). It is for those who are not on medication or are on a stable single medication, and whose blood pressure is moderately high but not extremely high.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Peoria, ArizonaAges 16–80 - NCT07191249RecruitingPhase 2
Mosunetuzumab for low-tumor-burden follicular lymphoma
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
HaifaAges 18 years+ - NCT06945614RecruitingPhase 1
Xenon gas for brain inflammation safety study
This study tests an inhaled gas called xenon to see if it can safely reduce brain inflammation. The study is for healthy volunteers aged 55-75 to check safety and early signs of benefit.
Boston, MassachusettsAges 55–75 - NCT07185932RecruitingEarly Phase 1
Rifaximin for fatty liver with metabolic issues
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07191431Recruiting
Study of drug combo for returning brain lymphoma
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07185451Recruiting
Brain stimulation for teens with depression
This trial tests if a gentle electrical brain stimulation called tACS can help teens with depression who are already on stable medication. The treatment is added to their usual medication to see if it improves mood.
Chongqing, Chongqing MunicipalityAges 12–18 - NCT07185503Recruiting
Testing two antifungal drugs for mucormycosis with blood cancer
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
DalianAges 18–65 - NCT07185035RecruitingEarly Phase 1
Testing natural killer cells for leftover lung nodules
This trial is testing a new treatment using your own immune cells (called NK cells) to fight leftover high-risk lung nodules that cannot be surgically removed. It is for people who have already had some cancerous nodules removed and are looking for another option.
NanjingAges 18–70 - NCT07187167RecruitingPhase 2
Lenalidomide and dexamethasone for Rosai-Dorfman disease
This trial tests a combination of two drugs, lenalidomide and dexamethasone (called the RD regimen), for people with Rosai-Dorfman disease, a rare disorder that causes immune cells to build up in the body. Researchers want to see if this treatment is safe and effective for patients who are newly diagnosed or whose disease has come back or not improved with other treatments.
BeijingAges 18–80
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.